Results 141 to 150 of about 976 (152)

Clinical outcomes in patients with ST-segment elevation myocardial infarction treated with everolimus-eluting stents versus bare-metal stents (EXAMINATION): 5-year results of a randomised trial

Lancet, The, 2016
Manel Sabaté Tenas, Salvatore Brugaletta, Ángel Cequier   +2 more
exaly  

Very thin strut biodegradable polymer everolimus-eluting and sirolimus-eluting stents versus durable polymer zotarolimus-eluting stents in allcomers with coronary artery disease (BIO-RESORT): a three-arm, randomised, non-inferiority trial

Lancet, The, 2016
Clemens Von Birgelen C, Marlies M Kok, Liefke van der Heijden   +2 more
exaly  

Ultrathin-strut, biodegradable-polymer, sirolimus-eluting stents versus thin-strut, durable-polymer, everolimus-eluting stents for percutaneous coronary revascularisation: 5-year outcomes of the BIOSCIENCE randomised trial

Lancet, The, 2018
Thomas M Pilgrim, Raffaele Piccolo, Dik Heg   +2 more
exaly  

A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents

Lancet, The, 2004
Mark J Eisenberg
exaly  

Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial

Lancet, The, 2011
Giulio G Stefanini, Bindu Kalesan, Patrick W Serruys   +2 more
exaly  

Prostheses, Stents, and Splints for the Oral Cancer Patient

Ca-A Cancer Journal for Clinicians, 1968
exaly  

Third-generation zotarolimus-eluting and everolimus-eluting stents in all-comer patients requiring a percutaneous coronary intervention (DUTCH PEERS): a randomised, single-blind, multicentre, non-inferiority trial

Lancet, The, 2014
Clemens Von Birgelen C, Gerard C M Linssen, Carine J M Doggen   +2 more
exaly  

Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trial

Lancet, The, 2017
David E Kandzari, Hector M Garcia-Garcia, Johan Bennett   +2 more
exaly  

Drug-eluting stents in elderly patients with coronary artery disease (SENIOR): a randomised single-blind trial

Lancet, The, 2018
Olivier Varenne, Stephane Cook, Sasko Kedev,, Fscai   +2 more
exaly  

Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled trials

Lancet, The, 2016
Salvatore Cassese, Gjin Ndrepepa, Sebastian Kufner   +2 more
exaly